AI robots emerge as new competitive frontier for automakers
The convergence of AI robotics and automotive manufacturing presents a critical turning point for the industry. As automakers explore artificial…
FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
The FDA approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain…
Drug Trials Snapshot: LIVTENCITY
LIVTENCITY is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease.
Drug Trials Snapshots: BIMZELX
BIMZELX is an anti-interleukin (IL)-17A and IL-17F monoclonal antibody that is indicated for the treatment of adults with moderate to…
Drug Trials Snapshots: LEQSELVI
LEQSELVI is a Janus kinase (JAK) inhibitor that is indicated for the treatment of adults with severe alopecia areata (AA).
Drug Trials Snapshot: NEXVIAZYME
NEXVIAZYME is an enzyme used for the treatment of patients 1 year of age and older with late-onset Pompe disease…
FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy
[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis…
Spotlight on CDER Science
FDA scientists carry out laboratory, clinical and analytical research to address knowledge gaps in drug development, healthcare technologies and post-market…
CDER Communications Testing: Optimizing Drug Information Through Target Audience Feedback
Social and behavioral scientists in CDER’s Office of Communications (OCOMM) collect feedback from target audience members on a variety of…
FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)
A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting…